ArticleCureus2025
Achieving 100% Uptake of Intravenous Zoledronic Acid After Hip Fracture Through Rapid Vitamin D Loading: A Three-Cycle Quality Improvement Study in a District General Hospital.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHip fracture patients are at high risk of secondary fractures. National guidance and the consensus from the literature recommend timely bone protection therapy. Delays in vitamin D testing and logistical barriers often prevent inpatient intravenous (IV) zoledronic acid use. Our aim was to determine whether a rapid vitamin D loading protocol enabling inpatient IV zoledronic acid administration before discharge could improve treatment uptake and meet national standards.
methodsA three-cycle quality improvement project was conducted in patients aged ≥60 years with fragility hip fractures. Baseline data (2020-2022) were compared to post-intervention cycles (2024-2025). The intervention comprised a standard operating procedure (SOP) incorporating ≥160,000 IU cholecalciferol loading over seven days, renal and calcium monitoring, pre- and post-infusion checklists, and inpatient IV zoledronic acid on or after day 5 post-surgery. The primary outcome was receipt of IV zoledronic acid. Secondary measures included vitamin D result availability, process compliance, and safety outcomes.
resultsAt baseline, seven out of 29 patients (24.1%) received IV zoledronic acid. Post-intervention, all eligible patients (100%) (Cycle 2: 30/30; Cycle 3: 80/80) received inpatient IV zoledronic acid (
conclusionA rapid vitamin D loading SOP enabled timely inpatient IV zoledronic acid administration, overcoming logistical and laboratory barriers and achieving 100% compliance with national standards without adverse effects. This pathway is safe, sustainable, and scalable for secondary fracture prevention in district general hospitals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.